December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

4.800 +0.570 (+13.48%)
Official Closing Price Updated: 4:00 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
ADC Therapeutics SA (ADCT) Q2 2021 Earnings Call Transcript ↗
ADCT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
From ADC Therapeutics SA
Via Business Wire
News headline image
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
News headline image
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
From ADC Therapeutics SA
Via Business Wire
News headline image
Expert Ratings for ADC Therapeutics ↗
Within the last quarter, ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 2 1... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 ↗
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
News headline image
ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
News headline image
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
News headline image
ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology
From ADC Therapeutics SA
Via Business Wire
News headline image
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
News headline image
ADC Therapeutics SA (ADCT) Q1 2021 Earnings Call Transcript ↗
ADCT earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics’ ZYNLONTA™ (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics to Participate in May Investor Conferences
From ADC Therapeutics SA
Via Business Wire
News headline image
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates ↗
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD) Nuplazid... 
Via Benzinga
News headline image
ADC Therapeutics to Host First Quarter 2021 Financial Results Conference Call on May 6, 2021
From ADC Therapeutics SA
Via Business Wire
News headline image
ADC Therapeutics Stock Jumps On Scoring First FDA Approval For DLBCL Treatment ↗
ADC Therapeutics SA (NYSE: ADCT) has scored an FDA approval for Zynlonta, formerly known as loncastuximab tesirine, as a solo treatment for adult patients... 
Via Benzinga
News headline image
ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.